Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.

Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, Khurmi NS, Mentz RJ, Oulhaj A, Buse JB, Chan JC, Iqbal N, Kundu S, Maggioni AP, Marso SP, Öhman P, Pencina MJ, Poulter N, Porter LE, Ramachandran A, Zinman B, Hernandez AF.

Am Heart J. 2016 Apr;174:103-10. doi: 10.1016/j.ahj.2015.12.009. Epub 2015 Dec 21.

PMID:
26995376
2.

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes.

Riddle MC, Yuen KC, de Bruin TW, Herrmann K, Xu J, Öhman P, Kolterman OG.

Diabetes Obes Metab. 2015 Sep;17(9):904-7. doi: 10.1111/dom.12504. Epub 2015 Jul 8.

3.

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes.

Iqbal N, Allen E, Öhman P.

Clin Interv Aging. 2014 Sep 4;9:1479-87. doi: 10.2147/CIA.S68193. eCollection 2014.

4.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

5.

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.

Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DL.

Diabetes Metab Res Rev. 2013 Jul;29(5):417-26. doi: 10.1002/dmrr.2413. Epub 2013 May 21.

PMID:
23564755
6.

Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.

Lindblom P, Berg AL, Zhang H, Westerberg R, Tugwood J, Lundgren H, Marcusson-Ståhl M, Sjögren N, Blomgren B, Öhman P, Skånberg I, Evans J, Hellmold H.

Toxicol Pathol. 2012;40(1):18-32. doi: 10.1177/0192623311429972. Epub 2011 Nov 30.

7.

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Price DL, Chen R, Udell J, Raz I.

Am Heart J. 2011 Nov;162(5):818-825.e6. doi: 10.1016/j.ahj.2011.08.006.

PMID:
22093196
8.

Comment on Gerich--DPP-4 inhibitors: what may be the clinical differentiators?

Chen R, Ohman P, Kirby M.

Diabetes Res Clin Pract. 2011 Jul;93(1):e3-4. doi: 10.1016/j.diabres.2011.03.008. Epub 2011 Apr 3. No abstract available.

PMID:
21459471
9.

Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin-angiotensin-aldosterone system.

Ekman B, Ohman PK, Arnqvist HJ, Lindström T, Nyström FH.

Clin Endocrinol (Oxf). 2002 Oct;57(4):473-9.

PMID:
12354129
10.
12.
13.

[Prolactin--a hormone with many effects].

Werner S, Bengtsson BA, Petruson B, Karlsson A, Bolander H, Bramnert M, Valdemarsson S, Bynke O, Ohman P, Olsson T, Rasmuson T, Anggård A.

Lakartidningen. 1999 Mar 10;96(10):1171-4. Review. Swedish. No abstract available.

PMID:
10193120
14.
15.

[A case report. Bronchial ACTH producing carcinoid].

Bergmark V, Ohman P, Karlberg BE, Smeds S.

Lakartidningen. 1997 Mar 12;94(11):964-6. Swedish. No abstract available.

PMID:
9102539
16.

Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables.

Nyström FH, Ohman PK, Ekman BA, Osterlund MK, Karlberg BE, Arnqvist HJ.

Eur J Endocrinol. 1997 Feb;136(2):165-72.

PMID:
9116911
17.

Chimeric macaque/human Fab molecules neutralize simian immunodeficiency virus.

Samuelsson A, Chiodi F, Ohman P, Putkonen P, Norrby E, Persson MA.

Virology. 1995 Mar 10;207(2):495-502.

18.

Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques.

Zhang YJ, Putkonen P, Albert J, Ohman P, Biberfeld G, Fenyö EM.

Virology. 1994 May 1;200(2):583-9.

PMID:
7909969
19.

Autologous neutralizing antibodies to SIVsm in cynomolgus monkeys correlate to prognosis.

Zhang YJ, Ohman P, Putkonen P, Albert J, Walther L, Stålhandske P, Biberfeld G, Fenyö EM.

Virology. 1993 Dec;197(2):609-15.

PMID:
7902628
20.

[Effective blood pressure reduction and few side-effects in treatment with captopril and diuretics].

Nilsson O, Karlberg BE, Wettre S, Ohman P, Andersson PO, Engström M, Kuylenstierna J, Ottosson AM, Sjöstrand A.

Lakartidningen. 1985 Jun 26;82(26-27):2430-3. Swedish. No abstract available.

PMID:
3892203
Items per page

Supplemental Content

Loading ...
Write to the Help Desk